Sandro M Wagner - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

European Journal of Haematology|December 16, 2019

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomasSandro M Wagner, Thomas Melchardt, Alexander Egle, et al.

Anticancer Research|February 28, 2023

Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck CancerSandro M Wagner, Teresa Magnes, Thomas Melchardt, et al.

Wiener Klinische Wochenschrift|September 16, 2021

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMTTeresa Magnes, Sandro M Wagner, Thomas Melchardt, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

European Journal of Haematology|December 16, 2019

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomasSandro M Wagner, Thomas Melchardt, Alexander Egle, et al.

Anticancer Research|February 28, 2023

Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck CancerSandro M Wagner, Teresa Magnes, Thomas Melchardt, et al.

Wiener Klinische Wochenschrift|September 16, 2021

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMTTeresa Magnes, Sandro M Wagner, Thomas Melchardt, et al.

Pageof 1